Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tobemstomig Combinations in Advanced Renal Cell Carcinoma
NCT05805501Phase 2Completed
- Sponsor
- Roche
- Start
- Apr 2023
- Primary completion
- Oct 2026
- Modality
- Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 9
01
Overview
A Phase 2 trial of tobemstomig in renal cell carcinoma (RCC), sponsored by Roche. Started Apr 2023; status: completed.
02
Drugs
tobemstomig
03
Conditions
renal cell carcinoma (RCC)
Beyond the preview
Go deeper on NCT05805501.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05805501.